PharmaShots | Incisive News in 3 Shots

Subscribe Now

Synaffix

Synaffix Entered into a License Agreement with Chong Kun Dang Pharm for ADC Technology

Synaffix Entered into a License Agreement with Chong Kun Dang Pharm for ADC Technology

February 6, 2023

Synaffix Entered into a License Agreement with Amgen to Develop Antibody-Drug Conjugates to Treat Cancer

Synaffix Entered into a License Agreement with Amgen to Develop Antibody-Drug Conjugates to Treat Cancer

January 6, 2023

Synaffix Out-Licenses ADC Technology Platform to Emergence for Cancer

Synaffix Out-Licenses ADC Technology Platform to Emergence for Cancer

September 7, 2022

Synaffix Expands the License Agreement with Mersana to Develop ADCs Targeting Cancers for ~$1B

Synaffix Expands the License Agreement with Mersana to Develop ADCs Targeting Cancers for ~$1B

December 1, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us